Multiplicom is proud to launch Clarigo™, a new CE-IVD1 non-invasive prenatal test (NIPT). This highly accurate blood test will enable genetic analysis laboratories to detect the presence or absence of major chromosomal abnormalities such as trisomy 21 (Down’s syndrome), 18 (Edwards’ syndrome) and 13 (Patau syndrome), in the fetus, as early as in the first trimester of pregnancy by analysis of the fetus’s DNA in the maternal blood.

Clarigo enables an optimal workflow for low to high throughput sample processing that further reduces the overall cost to a level that will make NIPT affordable for all pregnant women as an integral part of prenatal care.

The targeted design of Clarigo enables highly accurate trisomy calling of chromosomes 21, 18 and 13 based on only 2M reads per sample, which is several times less than for generally used shotgun approaches. Data analysis and interpretation is automated with the dedicated Clarigo™ Reporter software developed at Multiplicom and empowered by proprietary algorithms. The Clarigo Reporter further includes an intrinsic quality control assessment and provides information on the fetal fraction for each sample and optionally on fetal gender.